Name: VERU INC (VERU) Stock
Brand: VERU INC
Rating: 3.5 (3 reviews)

VERU Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Veru Inc.

Veru to Report Fiscal Year 2025 Financial Results on December 17th

10 days ago - By: Veru Inc.

Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop

a month ago - By: Veru Inc.

Veru to Present Two Abstracts at ObesityWeek 2025

a month ago - By: Benzinga - Mentions: HBIO IART EBS GH ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 months ago - By: Veru Inc.

Veru Announces Proposed Public Offering

4 months ago - By: Benzinga

A Look Ahead: Veru's Earnings Forecast

4 months ago - By: Veru Inc.

Veru Announces Reverse Stock Split

2 months ago - By: Veru Inc.

Veru Announces Pricing of $25 Million Public Offering

3 months ago - By: Veru Inc.

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

4 months ago - By: Zacks Investment Research - Mentions: REGN LLY SRRK

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm

4 months ago - By: Veru Inc.

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

4 months ago - By: Veru Inc.

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

4 months ago - By: Veru Inc.

Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

5 months ago - By: Veru Inc.

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

6 months ago - By: Veru Inc.

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation

6 months ago - By: Veru Inc.

Veru to Participate in the Virtual BTIG Obesity Health Forum

7 months ago - By: Veru Inc.

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

7 months ago - By: Veru Inc.

Veru Participates in a Virtual Investor KOL Connect Segment

7 months ago - By: Veru Inc.

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

8 months ago - By: Veru Inc.

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

8 months ago - By: Veru Inc.

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

9 months ago - By: Veru Inc.

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

10 months ago - By: Veru Inc.

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

10 months ago - By: Veru Inc.

VERU INC (VERU) Stock News

VERU Latest News, Press Relases and Analysis

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop

Veru to Present Two Abstracts at ObesityWeek 2025

12 Health Care Stocks Moving In Thursday's Intraday Session

Veru Announces Proposed Public Offering

A Look Ahead: Veru's Earnings Forecast

Veru Announces Reverse Stock Split

Veru Announces Pricing of $25 Million Public Offering

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation

Veru to Participate in the Virtual BTIG Obesity Health Forum

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

Veru Participates in a Virtual Investor KOL Connect Segment

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference